AMR announce Pediatric Drug Development Market - Global Industry Analysis 2023
Acute Market Reports has announced the addition of the "Pediatric Drug Development Market - Global Industry Analysis 2023" report to their offering.
<p>Although pediatrics represent around two-fifths of the global population the market for pediatric medicines remains relatively small (accounting for <10% of global pharmaceutical sales). Until pediatric legislation was introduced in the US (1997) and EU (2007) there has been little incentive for the pharma industry to evaluate drugs in children due to the low medical need of chronic illnesses and the high off-label use of generic drugs (Milne & Bruss, 2008). </p> <p>Since the introduction of pediatric legislation there has been a substantial investment in pediatric research and the number of clinical trials performed in children has increased significantly. In the US more than 350 product labels include new pediatric information and more than 130 products have undergone a pediatric focused post-labelling safety review. In Europe there has been 221 changes regarding the safety and efficacy of medicines from the submission of old or new studies in children and 89 additions of dosing information for children as a direct consequence of Paediatric Investigation Plans (PIPs). </p> <p>Browse Here For Full Report : <a href="http://www.acutemarketreports.com/report/pediatric-drug-development-market">http://www.acutemarketreports.com/report/pediatric-drug-development-market</a></p> <p>Despite the apparent success of the pediatric regulation, the submission of pediatric information is complex and the incentives are often insufficient to encourage industry innovation (Rose & Della Pasqua, 2011). No new drugs can be registered in the EU without a detailed PIP being approved by the EMA’s Pediatric Committee (PDCO) (Rose, 2014). Without a PIP, the registration process for a new drug can be blocked. In the US, the FDA has adopted a more pragmatic approach to pediatric drug development, providing voluntary and mandatory routes for pediatric evaluation. </p> <p> </p> <p>Request For Free Sample of This report : <a href="http://www.acutemarketreports.com/request-free-sample/35393">http://www.acutemarketreports.com/request-free-sample/35393</a></p> <p>Key Reasons to Purchase</p> <p> </p> <p>Contact: </p> <p>Chris Paul </p> <p>Office No 01, 1st Floor, </p> <p>Aditi Mall, Baner, Pune, </p> <p>MH, 411045 India </p> <p>Phone (INDIA): +91 7755981103</p> <p>Toll Free(US/CANADA):+1-855-455-8662 </p> <p>Email: email@example.com</p> <p>Website: www.acutemarketreports.com/</p> <p> </p>